Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their...
SAN FRANCISCO , May 18, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. ( NASDAQ: GOSS ) and an executive, seeking to represent investors who...
Gossamer Bio, Inc. (NASDAQ: GOSS) (the “Company”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH)...
- FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June - - Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension...
NEW YORK , May 14, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors...
BENSALEM, Pa. , May 14, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...
SAN FRANCISCO , May 14, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. ( NASDAQ: GOSS ) and an executive, seeking to represent investors who...
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their Options